Exemestane Monotherapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Regulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer | 3 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | ER positive, PR positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | ER positive | Invasive Breast Carcinoma | Exemestane | |
| Sensitivity (+) | PR positive | Invasive Breast Carcinoma | Exemestane |